Establishment and validation of an immune-associated signature in lung adenocarcinoma
Zhenyu Wang et al, 2020, International Immunopharmacology CrossRef
Protein array-based companion diagnostics in precision medicine
Thomas B. G. Poulsen et al, 2020, Expert Review of Molecular Diagnostics CrossRef
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Giovanna Mirone et al, 2016, Resistance to Tyrosine Kinase Inhibitors CrossRef
Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer
Sara K. Jaradat et al, 2024, Technology in Cancer Research & Treatment CrossRef
A study of the prognostic and predictive role of HER-2 expression in bladder urothelial carcinoma
Nanis Shawky Holah et al, 2016, Egyptian Journal of Pathology CrossRef
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
Yijia Guo et al, 2020, Frontiers in Oncology CrossRef
Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
Carla Colombo et al, 2022, Frontiers in Oncology CrossRef
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Matteo Canale et al, 2017, Clinical Cancer Research CrossRef
Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
Fred R. Hirsch et al, 2018, Cancer CrossRef
Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell
Julieti Huch Buss et al, 2019, Frontiers in Oncology CrossRef
Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
Shuzo Tamura et al, 2018, Bladder Cancer CrossRef
Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Cecilie Budolfsen et al, 2019, Current Vascular Pharmacology CrossRef